TY - JOUR
T1 - Clinical spectrum and genotype-phenotype associations of KCNA2-related encephalopathies
AU - Masnada, Silvia
AU - Hedrich, Ulrike B.S.
AU - Gardella, Elena
AU - Schubert, Julian
AU - Kaiwar, Charu
AU - Klee, Eric W.
AU - Lanpher, Brendan C.
AU - Gavrilova, Ralitza H.
AU - Synofzik, Matthis
AU - Bast, Thomas
AU - Gorman, Kathleen
AU - King, Mary D.
AU - Allen, Nicholas M.
AU - Conroy, Judith
AU - Ben Zeev, Bruria
AU - Tzadok, Michal
AU - Korff, Christian
AU - Dubois, Fanny
AU - Ramsey, Keri
AU - Narayanan, Vinodh
AU - Serratosa, Jose M.
AU - Giraldez, Beatriz G.
AU - Helbig, Ingo
AU - Marsh, Eric
AU - O'Brien, Margaret
AU - Bergqvist, Christina A.
AU - Binelli, Adrian
AU - Porter, Brenda
AU - Zaeyen, Eduardo
AU - Horovitz, Dafne D.
AU - Wolff, Markus
AU - Marjanovic, Dragan
AU - Caglayan, Hande S.
AU - Arslan, Mutluay
AU - Pena, Sergio D.J.
AU - Sisodiya, Sanjay M.
AU - Balestrini, Simona
AU - Syrbe, Steffen
AU - Veggiotti, Pierangelo
AU - Lemke, Johannes R.
AU - Møller, Rikke S.
AU - Lerche, Holger
AU - Rubboli, Guido
N1 - Funding Information:
NIHR Biomedical Research Centres funding scheme, Wellcome Trust Strategic Award (WT104033AIA), the Epilepsy Society and The Muir Maxwell Trust to S.M.S and S.S; donations to the Center for Rare Childhood Disorders and from the State of Arizona to K.R. and V.N.; Else Kröner Fresenius Stiftung to M.S.; intramural funds of the University of Kiel, grant from the German Research Foundation (HE5415/3-1) within the EuroEPINOMICS framework of the European Science Foundation and grants of the German Research Foundation (DFG, HE5415/5-1, HE5415/6-1), German Ministry for Education and Research (01DH12033, MAR 10/012), the German chapter of the International League against Epilepsy (DGfE) to I.H.; EuroEPINOMICS frame-work of the European Science Foundation (DFG grant
Funding Information:
Le1030/11-2), by the German Ministry for Education and Research (BMBF) rare disease network IonNeurONet (01GM1105A), as well as the German chapter of the International League Against Epilepsy (DGfE) and the foundation “no epilep” to H.L; TUBITAK project no 110S518 within the Euroepinomics-RES network to H.S.C. I.H. has also received support through the International League Against Epilepsy (ILAE) within the Epilepsiome initiative of the ILAE Genetics Commission (www.channelopathist.net).
Publisher Copyright:
© The Author (2017). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved.
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Recently, de novo mutations in the gene KCNA2, causing either a dominant-negative loss-of-function or a gain-of-function of the voltage-gated K+ channel Kv1.2, were described to cause a new molecular entity within the epileptic encephalopathies. Here, we report a cohort of 23 patients (eight previously described) with epileptic encephalopathy carrying either novel or known KCNA2 mutations, with the aim to detail the clinical phenotype associated with each of them, to characterize the functional effects of the newly identified mutations, and to assess genotype-phenotype associations. We identified five novel and confirmed six known mutations, three of which recurred in three, five and seven patients, respectively. Ten mutations were missense and one was a truncation mutation; de novo occurrence could be shown in 20 patients. Functional studies using a Xenopus oocyte two-micro-electrode voltage clamp system revealed mutations with only loss-of-function effects (mostly dominant-negative current amplitude reduction) in eight patients or only gain-of-function effects (hyperpolarizing shift of voltage-dependent activation, increased amplitude) in nine patients. In six patients, the gain-of-function was diminished by an additional loss-of-function (gain-and loss-of-function) due to a hyperpolarizing shift of voltage-dependent activation combined with either decreased amplitudes or an additional hyperpolarizing shift of the inactivation curve. These electrophysiological findings correlated with distinct phenotypic features. The main differences were (i) predominant focal (loss-of-function) versus generalized (gain-of-function) seizures and corresponding epileptic discharges with prominent sleep activation in most cases with loss-of-function mutations; (ii) more severe epilepsy, developmental problems and ataxia, and atrophy of the cerebellum or even the whole brain in about half of the patients with gain-of-function mutations; and (iii) most severe early-onset phenotypes, occasionally with neonatal onset epilepsy and developmental impairment, as well as generalized and focal seizures and EEG abnormalities for patients with gain- and loss-of-function mutations. Our study thus indicates well represented genotype-phenotype associations between three subgroups of patients with KCNA2 encephalopathy according to the electrophysiological features of the mutations.
AB - Recently, de novo mutations in the gene KCNA2, causing either a dominant-negative loss-of-function or a gain-of-function of the voltage-gated K+ channel Kv1.2, were described to cause a new molecular entity within the epileptic encephalopathies. Here, we report a cohort of 23 patients (eight previously described) with epileptic encephalopathy carrying either novel or known KCNA2 mutations, with the aim to detail the clinical phenotype associated with each of them, to characterize the functional effects of the newly identified mutations, and to assess genotype-phenotype associations. We identified five novel and confirmed six known mutations, three of which recurred in three, five and seven patients, respectively. Ten mutations were missense and one was a truncation mutation; de novo occurrence could be shown in 20 patients. Functional studies using a Xenopus oocyte two-micro-electrode voltage clamp system revealed mutations with only loss-of-function effects (mostly dominant-negative current amplitude reduction) in eight patients or only gain-of-function effects (hyperpolarizing shift of voltage-dependent activation, increased amplitude) in nine patients. In six patients, the gain-of-function was diminished by an additional loss-of-function (gain-and loss-of-function) due to a hyperpolarizing shift of voltage-dependent activation combined with either decreased amplitudes or an additional hyperpolarizing shift of the inactivation curve. These electrophysiological findings correlated with distinct phenotypic features. The main differences were (i) predominant focal (loss-of-function) versus generalized (gain-of-function) seizures and corresponding epileptic discharges with prominent sleep activation in most cases with loss-of-function mutations; (ii) more severe epilepsy, developmental problems and ataxia, and atrophy of the cerebellum or even the whole brain in about half of the patients with gain-of-function mutations; and (iii) most severe early-onset phenotypes, occasionally with neonatal onset epilepsy and developmental impairment, as well as generalized and focal seizures and EEG abnormalities for patients with gain- and loss-of-function mutations. Our study thus indicates well represented genotype-phenotype associations between three subgroups of patients with KCNA2 encephalopathy according to the electrophysiological features of the mutations.
KW - Encephalopathy
KW - Gain-of-function
KW - KCNA2
KW - Loss-of-function
KW - Phenotype-genotype associations
UR - http://www.scopus.com/inward/record.url?scp=85031825168&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031825168&partnerID=8YFLogxK
U2 - 10.1093/brain/awx184
DO - 10.1093/brain/awx184
M3 - Article
C2 - 29050392
AN - SCOPUS:85031825168
SN - 0006-8950
VL - 140
SP - 2337
EP - 2354
JO - Brain
JF - Brain
IS - 9
ER -